Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)

NCT04851964 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04851964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04851964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 22, 2021
Completion date
December 11, 2024
Enrollment
416 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps